TFA
SRPT icon

Transamerica Financial Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Transamerica Financial Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341 Buy
19
+14
+280% +$265 ﹤0.01% 1771
2026
Q1 		$108 Buy
5
+4
+400% +$77 ﹤0.01% 1729
2025
Q4 		$22 Sell
1
-6
-86% -$126 ﹤0.01% 1816
2025
Q3 		$135 Buy
+7
New +$125 ﹤0.01% 1489

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Transamerica Financial Advisors's SRPT Position: Q2 2026 in Review

Transamerica Financial Advisors increased its Sarepta Therapeutics (SRPT) stake by 280% in Q2 2026, buying an estimated $265 and bringing the position to 19 shares worth $341. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

Transamerica Financial Advisors first reported a position in SRPT in Q3 2025 and has held it in 4 quarters since. 321 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Transamerica Financial Advisors held 19 shares of Sarepta Therapeutics worth $341 as of Q2 2026.
  • Transamerica Financial Advisors bought 14 Sarepta Therapeutics shares in Q2 2026, an estimated $265.
  • Sarepta Therapeutics made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1771 holding.
  • Transamerica Financial Advisors first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 321 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.